Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V97196 | ADC Control Human IgG1-Deruxtecan (DAR 8) | ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that serves as an isotype control for the ADC Human IgG1-Deruxtecan, which inhibits DNA topoisomerase I. | |
![]() |
V94359 | Anti-CD22-NMS249 | Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC) composed of the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor. | |
![]() |
V78751 | Exatecan Intermediate 3 | Exatecan Intermediate 3 is the intermediate of Exatecan. | |
![]() |
V94122 | FZ-AD005 | FZ-AD005 is a DLL3-targeted ADC containing a novel anti-DLL3 antibody, FZ-A038, and a valine-alanine (Val-Ala) dipeptide linker. | |
![]() |
V76158 | Izeltabart (IMGC-936) | 2642078-60-0 | Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9. |
![]() |
V53069 | KRAS degrader-1 | 2795275-59-9 | KRAS degrader-1 (compound 1) is a potent KRAS degrader. |
![]() |
V88375 | ORM-5029 | ORM-5029 is the first antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), which is a combination of the highly effective GSPT1 degrader SMol006 and Pertuzumab. | |
![]() |
V94455 | Raludotatug Deruxtecan | Raludotatug Deruxtecan (DS-6000) is a novel antibody-drug conjugate (ADC) targeting CDH6. | |
![]() |
V81404 | SMP-33693 | SMP-33693 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer. | |
![]() |
V81405 | SMP-88480 | SMP-88480 is an Antibody-Drug Conjugates (ADCs). | |
![]() |
V81406 | SMP-93566 | SMP-93566 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor suppressive effects on ovarian cancer, gastric cancer, and breast cancer. |